1. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia by Alessandra Ferrajoli, Tait D. Shanafelt, Cristina Ivan, Masayoshi Shimizu, Kari G. Rabe, Nazila Nouraee, Mariko Ikuo, Asish K. Ghosh, Susan Lerner, Laura Z. Rassenti, Lianchun Xiao, Jianhua Hu, James M. Reuben, Steliana Calin, M. James You, John T. Manning, William G. Wierda, Zeev Estrov, Susan O’Brien, Thomas J. Kipps, Michael J. Keating, Neil E. Kay, and George A. Calin Blood Volume 122(11):1891-1899 September 12, 2013 ©2013 by American Society of Hematology

2. miR-155 levels in normal B cells, MBL cells, and CLL cells as measured by qRT-PCR. Alessandra Ferrajoli et al. Blood 2013;122:1891-1899 ©2013 by American Society of Hematology

3. Relationship between relative miR-155 expression levels in plasma and response to therapy in group C. (A) Relative expression levels of miR-155 in plasma were lower in patients treated with fludarabine, cyclophosphamide, and rituximab who experienced a comp... Alessandra Ferrajoli et al. Blood 2013;122:1891-1899 ©2013 by American Society of Hematology

4. Relationship between relative miR-155 expression levels in plasma and overall survival in patients in group C. (A) Kaplan-Meier survival curves according to relative expression levels of miR-155 in plasma (low, up to 56th percentile; high, above 56th percen... Alessandra Ferrajoli et al. Blood 2013;122:1891-1899 ©2013 by American Society of Hematology

5. Relationship between relative miR-155 expression levels in plasma and response to treatment in patients in groups D and E. Relative expression levels of miR-155 in plasma were significantly higher in patients who achieved a complete response than in patient... Alessandra Ferrajoli et al. Blood 2013;122:1891-1899 ©2013 by American Society of Hematology